TREACE MEDICAL CONCEPTS INC
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
TMCI$4.03-3.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $9,334 | $12,982 |
| Marketable securities, short-term | 100,672 | 110,216 |
| Accounts receivable, net of allowance for doubtful accounts of $1,076 and $980 as of March 31, 2024 and December 31, 2023, respectively | 30,083 | 38,063 |
| Inventories | 35,860 | 29,245 |
| Prepaid expenses and other current assets | 11,448 | 7,853 |
| Total current assets | 187,397 | 198,359 |
| Property and equipment, net | 24,517 | 22,298 |
| Intangible assets, net of accumulated amortization of $713 and $475 as of March 31, 2024 and December 31, 2023, respectively | 8,787 | 9,025 |
| Goodwill | 12,815 | 12,815 |
| Operating lease right-of-use assets | 9,064 | 9,264 |
| Other non-current assets | 146 | 146 |
| Total assets | $242,726 | $251,907 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $21,149 | $11,835 |
| Accrued liabilities | 15,155 | 10,458 |
| Accrued commissions | 5,527 | 10,759 |
| Accrued compensation | 4,196 | 7,549 |
| Other liabilities | 1,022 | 4,432 |
| Total current liabilities | 47,049 | 45,033 |
| Long-term debt, net of discount of $917 and $992 as of March 31, 2024 and December 31, 2023, respectively | 53,083 | 53,008 |
| Operating lease liabilities, net of current portion | 16,166 | 15,891 |
| Other long-term liabilities | 37 | 37 |
| Total liabilities | 116,335 | 113,969 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value, 300,000,000 shares authorized; 61,948,776 and 61,749,654 issued, and 61,929,172 and 61,749,654 outstanding as of March 31, 2024 and December 31, 2023, respectively | 62 | 62 |
| Additional paid-in capital | 279,433 | 271,973 |
| Accumulated deficit | (152,923) | (134,247) |
| Accumulated other comprehensive (loss) income | 69 | 163 |
| Treasury stock, at cost; 19,604 and 1,218 shares as of March 31, 2024 and December 31, 2023, respectively | (250) | (13) |
| Total stockholders’ equity | 126,391 | 137,938 |
| Total liabilities and stockholders’ equity | $242,726 | $251,907 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.